Mumtaz Score for Readmission in Cirrhosis

The Mumtaz Score predicts 30‑day readmission risk in decompensated cirrhosis using demographics, comorbidities, complications, and key in‑hospital interventions 1 [Level II evidence].

Age, years
≥ 65040-64+418-39+7
Primary payer
Self-pay-3No charge or other-1Private insurance0Medicare+4Medicaid+5
Elixhauser Comorbidity Index
< 30≥ 3+2
Non-alcoholic etiology of cirrhosis
No0Yes+2
Ascites
No0Yes+5
Hepatic encephalopathy
No0Yes+4
Variceal bleeding
Yes-7No0
Hepatocellular carcinoma
No0Yes+3
Paracentesis during admission
No0Yes+4
Hemodialysis during admission
No0Yes+7
Disposition
Transfer-1Routine0Home health care+1Against medical advice+10

Indications d'utilisation

Used in hospitalized adults with decompensated cirrhosis at discharge to estimate 30‑day readmission risk based on demographics, decompensation features, and in‑hospital interventions. Derived from 123,011 patients and externally validated 1 [Level II evidence]. Helps stratify into low (<20%), medium (20–30%), and high (>30%) readmission risk to guide closer follow‑up and targeted post‑discharge interventions.

Informations et précautions

Identifies 30‑day readmission risk in decompensated cirrhosis but has modest discrimination (c‑statistic ≈0.64–0.70) and relies on administrative data with limited clinical granularity 1 [Level II evidence].
• Overweights inpatient complications (HE, infections, HD) and may misclassify compensated or atypical phenotypes.
• Not externally validated in contemporary cohorts and may underperform across etiologies, frailty levels, and ambulatory settings.